Clinical Trials
Explore Trial by Category
Neovascular Age-Related Macular Degeneration (Wet AMD)
Non-Exudative Age-Related Macular Degeneration (Dry AMD)
Diabetic Macular Edema (DME)
Diabetic Retinopathy
Uveitis
Branch Retinal Vein Occlusion (BRVO)
Central Retinal Vein Occlusion (CRVO)
Vitreomacular Adhesion
Vitreous Hemorrhage
Retinal Detachment
Macular Telangiectasia
Stargardt Disease
Neurotrophic Keratopathy
Neovascular Age-Related Macular Degeneration (Wet AMD)
Current Trials:
-
Sponsor – Genentech (Open to Enrollment)
+
Study: AVONELLE-X GR42691
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AVONELLE-X) -
Sponsor – Regenxbio (Recruitment/Not Yet Open)
+
Study: ASCENT RGX-314-3101
A Randomized, Partially Masked, Controlled, Phase 3 Clinical
Study to Evaluate the Efficacy and Safety of RGX-314 Gene
Therapy in Participants with nAMD -
Sponsor – Kodiak Sciences (Closed to Enrollment)
+
Study: DAYLIGHT KS301P107
A Prospective, Randomized, Double-masked, Active
Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to
Evaluate the Efficacy and Safety of Intravitreal KSI-301
Compared with Intravitreal Aflibercept in Participants with
Neovascular (Wet) Age-related Macular Degeneration (wAMD) -
Sponsor – F. Hoffmann-La Roche Ltd. (Open to Enrollment)
+
Study: BURGUNDY BP41670
A TWO-PART, PHASE I STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF RO7250284 FOLLOWING INTRAVITREAL ADMINISTRATION OF UNMASKED MULTIPLE ASCENDING DOSES AND MASKED SUSTAINED DELIVERY FROM THE PORT DELIVERY SYSTEM IN PATEINTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION -
Sponsor – Bayer/Regeneron (Closed to Enrollment)
+
Study: PULSAR 20968
Randomized, Double-Masked, Active-Controlled, Multi-Center Study Of Efficacy And Safety Of High Dose Aflibercept In Patients With Neovascular Age-Related Macular Degeneration -
Sponsor – Genentech/Roche (Open to Enrollment)
+
Study: PORTAL GR40549
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Previous Trials (2020 – Current):
-
Principal Investigator, 2020 – 2022
Sponsor – Genentech/Roche+
Study: ARCHWAY GR40548
A PHASE III, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED ACTIVE-COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENT WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION -
Principal Investigator, 2020 – 2022
Sponsor – Novartis+
Study: TALON RTH258
A 64-week, two-arm, randomized, double-masked, multi-center, phase IIIb study assessing the efficacy and safety of brolucizumab 6 mg compared to aflibercept 2 mg in a treat-to-control regimen in patients with neovascular age-related macular degeneration (TALON) -
Principal Investigator, 2020 – 2022
Sponsor – Novartis+
Study: MERLIN CRTH258AUS04
A multicenter, randomized, double-masked Phase 3a study to assess safety and efficacy of brolucizumab 6mg q4 weeks compared to aflibercept 2mg q4 weeks in patients with neovascular age-related macular degeneration (nAMD) with persistent retinal fluid (MERLIN) -
Principal Investigator, 2020 – 2022
Sponsor – Genentech/Roche+
Study: TENAYA GR40306
A PHASE III, MULTICENTER, RANDOMIZATION, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE FARICIMAB IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION -
Principal Investigator, 2020 – 2022
Sponsor – Chengdu Kanghong Biotechnology+
Study: PANDA KHB-1801
A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects with Neovascular Age-Related Macular Degeneration -
Principal Investigator, 2020 – 2022
Sponsor – Kodiak Sciences, Inc.+
Study: DAZZLE KSI-CL-201
A Phase 2, Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center Study to Investigate the Efficacy and Safety of Repeated Intravitreal Administration of KSI-301 in Subjects with Neovascular (Wet) Age-Related Macular Degeneration -
Principal Investigator, 2020 – 2022
Sponsor – Regeneron+
Study: CANDELA VGFTe (HD)-AMD-1905
A RANDOMIZED, SINGLE-MASKED, ACTIVE-CONTROLLED PHASE 2 STUDY OF THE SAFETY, TOLERABILITY, AND EFFICACY OF REPEATED DOSES OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION -
Principal Investigator, 2020 – 2022
Sponsor – Roche+
Study: BLUETAIL1 BP40923
A MULTI-CENTER, NON-RANDOMIZED, OPEN-LABEL, MULTIPLE ASCENDING DOSE STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF RO7200394 FOLLOWING INTRAVITREAL ADMINISTRATION IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. -
Principal Investigator, 2020-2020
Sponsor: Outlook Therapeutics+
Study: NORSE TWO
A CLINICAL EFFECTIVENESS, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF ONS-5010 IN SUBJECTS WITH SUBFOVEAL CHOROIDAL NEOVASCULARIZATION (CNV) SECONDARY TO AGE-RELATED MACULAR DEGENERATION (AMD)
Previous Trials (2015 – 2019):
-
Principal Investigator 2019 – 2020
Sponsor: Graybug Vision+
Study: ALTISSIMO
A Phase 1 / 2 Multicenter Study Evaluating the Safety, Tolerability, and Efficacy of an Intravitreal Depot Formulation of Sunitinib Malate (GB-102) in Subjects with Neovascular Age-related Macular Degeneration. -
Principal Investigator 2018 – 2019
Sponsor: Panoptica (Closed to Enrollment)+
Study: Panoptica (N/A)
A Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants with Neovascular Age-Related Macular Degeneration (AMD) -
Principal Investigator 2018 – 2020
Sponsor: Samsung Bioepis Co., LTD+
Study: Samsung (N/A)
A PHASE III RANDOMISED, DOUBLE-MASKED, PARALLEL GROUP, MULTICENTER STUDY TO COMPARE THE EFFICACY SAFETY, PARMACOKINETICS AND IMMUNOGENICITY BETWEEN SB11 (PROPOSED RANIBIZUMAB BIOSIMILAR) AND LUCENTIS IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION -
Principal Investigator 2017 – 2019
Sponsor: Genentech+
Study: LADDER
A PHASE II, MULTICENTER, RANDOMIZED, ACTIVE TREATMENT-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THE RANIBIZUMAB PORT DELIVERY SYSTEM FOR SUSTAINED DELIVERY OF RANIBIZUMAB IN PATIENTS WITH SUBFOVEAL NEOVASCULAR AGE-RELATED MACULAR DEGENERATION -
Principal Investigator 2016 – 2017
Sponsor: Ohr+
Study: MAKO
A Phase III Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution, 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration -
Principal Investigator 2015 – 2018
Sponsor: Allergan+
Study: SEQUOIA
SAFETY AND EFFICACY OF ABICIPAR PEGOL (AGN-150998) IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION -
Principal Investigator 2014 – 2017
Sponsor: Tyrogenex+
Study: APEX
A RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED, DOSE-FINDING, NON-INFERIORITY STUDY OF X-82 PLUS prn EYLEA COMPARED TO prn EYLEA MONOTHERAPY IN NEOVASCULAR AMD -
Principal Investigator 2016 – 2017
Sponsor: Regeneron+
Study: ONYX
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF REPEATED DOSES OF INTRAVITREAL REGN910-3 IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION -
Principal Investigator 2015 – 2017
Sponsor: Opthea+
A PHASE 1 DOSE ESCALATION STUDY EVALUATING THE SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF OPT-302 IN COMBINATION WITH RANIBIZUMAB IN SUBJECTS WITH WET AMD
-
Principal Investigator 2015 – 2017
Sponsor: Regeneron+
Study: CAPELLA
A PHASE 2, DOUBLE-MASKED, RANDOMIZED, CONTROLLED, MULTIPLE-DOSE, REGIMEN-RANGING STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL REGN2176-3 IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION -
Principal Investigator 2015 – 2016
Sponsor: Iconic+
Study: EMERGE
A PHASE 2 RANDOMIZED, DOUBLE-MASKED, MULTICENTER, ACTIVE-CONTROLLED STUDY EVALUATING ADMINISTRATION OF REPEATED INTRAVITREAL DOSES OF hI-con1 IN PATIENTS WITH CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR DEGENERATION -
Principal Investigator 2015 – 2016
Sponsor: Neurotech+
A MULTI-CENTER, TWO STAGE, OPEN-LABEL PHASE I AND RANDOMIZED ACTIVE CONTROLLED, MASKED PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF INTRAVITREAL IMPLANTATION OF NT-503-3 ENCAPSULATED CELL TECHNOLOGY COMPARED WITH EYLEA FOR THE TREAMENT OF RECURRENT SUBFOVEAL CHOROIDAL NEOVASCULARIZATION (CNV) SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Previous Trials (2010 – 2014):
-
Principal Investigator 2014 – 2016
Sponsor: PanOptica+
A PHASE I OPEN-LABEL, MUTLI-CENTER TRIAL WITH RANDOMIZATION TO DOSE TO EVALUATE THE SAFETY AND TOLERABILITY OF TOPICAL OCULAR PAN-90806 IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION (AMD)
-
Principal Investigator – 2013-2015
+
Phase 2 study of the efficacy and safety of Squalamine Lactate Ophthalmic Solution 0.2% twice daily in subjects with neovascular age-related macular degeneration
-
Principal Investigator, 2013 – 2015
+
Study: RE-VIEW
An Open-Label Study of the Efficacy, Safety, and Tolerability of Intravitreal Administration of VEGF Trap-Eye (Intravitreal Aflibercept Injection) in Patients with Neovascular Age-Related Macular Degeneration -
Sub-Investigator, 2010 – 2011
+
A Randomized, Sham-Injection Controlled, Double-Masked, Multicenter Trial of Ocriplasmin Intravitreal Injection for Treatment of Focal Vitreomacular Adhesion in Subjects with Exudative Age-Related Macular Degeneration (AMD)
-
Sub-Investigator, 2009 – 2012
+
Study: HARBOR
A Phase III, Multicenter, Randomized, Double-Masked Study Comparing the Efficacy and Safety of 0.5-mg and 2.0-mg Ranibizumab Administered Monthly or on an As-Needed Basis (PRN) with a Safety Run-In of a Single Dose of 2.0-mg Ranibizumab with Subfoveal Neovascular Age-Related Macular Degeneration
Previous Trials (2005 – 2009):
-
Sub-Investigator, 2008 – 2009
+
A 26-Week, Open Label Study to Assess the Safety and Efficacy of 700µg Dexamethasone Posterior Segment Drug Delivery System Applicator System as Adjunctive Therapy to Lucentis in the Treatment of Subjects with Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
-
Sub-Investigator, 2008 – 2009
+
A Phase 2 , Randomized, Masked, Controlled Clinical Study to Assess the Safety and Efficacy of Lucentis plus Sirolimus versus Lucentis plus Placebo in Patients with Sub-Foveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration
-
Sub-Investigator, 2007 – 2009
+
A Phase 3, Randomized, Double-Masked, Parallel-Assignment Study of Intravitreal Bevasiranib Sodium, Administered every 8 or 12 weeks as Maintenance Therapy Following Three Injections of Lucentis Compared with Lucentis Monotherapy every 4 weeks in Patients with Exudative Age-Related Macular Degeneration (AMD)
-
Sub-Investigator – 2008
+
Randomized, controlled trial of VEGF Trap in patients with neovascular AMD
-
Sub-Investigator, 2008
+
Study: DENALI
A 24-month Randomized, Double-masked, Controlled, Multicenter, Phase IIIB Study Assessing Safety and Efficacy of Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab Versus Ranibizumab Monotherapy in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration -
Sub-Investigator, 2006 – 2008
+
A 24-month randomized, double-masked, sham-controlled, multicenter, phase IIIB study comparing photodynamic therapy with verteporfin plus two different dose regimens of intravitreal triamcinolone acetonide (1mg and 4mg) versus Visudyne plus intravitreal pegaptanib (Macugen) in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration
-
Sub-Investigator, 2006 – 2008
+
An Evaluation of Efficacy and Safety of Posterior Juxtascleral Administrations of Anecortave Acetate for Depot Suspension (15mg or 30mg) versus Sham Administration in Patients at Risk for Developing Sight Threatening Choroidal Neovascularization Due to Exudative Age Related Macular Degeneration
-
Sub-Investigator, 2005 – 2007
+
Anecortave Acetate 15 mg Administered Every 3 Months Versus Anecortave Acetate 15 mg Administered Every 6 Months Versus Anecortave Acetate 30 mg Administered Every 6 Months in Patients With Exudative AMD.
-
Sub-Investigator, 2005
+
A Phase 3 Multi-Center, Randomized, Double-Masked, Controlled Study of Squalamine Lactate for Injection for the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration.
-
Sub-Investigator, 2005
+
A 24-month Randomized, Double-Masked, Sham-Controlled, Multi-Center, Phase 111B Study Comparing Photodynamic Therapy with Verteporfin Plus Two Different Dose Regimens of Intravitreal Triamcinolone Acetonide (1mg and 4mg) versus Visudyne Plus Intravitreal Pegaptanib (Macugen) in Patients with Subfoveal Choroidal Neovascularization Secondary to Age-Related Macular Degeneration.
Previous Trials (1998 – 2004):
-
Sub-Investigator, 1998 – 1999
+
A Phase III Randomized, Multi-Center, Double-Masked, Placebo-Controlled Parallel Group Study of Tin Ethyl Etiopurpurin (SnET2) Photodynamic Therapy in the Treatment of Subfoveal Choroidal Neovascularization Associated with Age-Related Macular Degeneration.
-
Sub-Investigator, 2002 – 2005
+
An Evaluation of Efficacy and Safety of Posterior Juxtascleral Injections of Anecortave Acetate 15 mg (0.5 mg of 30 mg/ml Anecortave Acetate Sterile Suspension) versus Visudyne in Patients with Subfoveal Exudative Age-Related Macular Degeneration (AMD) Eligible for Initial Treatment with Photodynamic Therapy (PDT) Using Visudyne.
-
Principal Investigator, 2002 – 2005
+
A Phase II/III Randomized, Double-Masked, Controlled, Dose Ranging, Multi-Center Comparative Trial, in Parallel Groups, to Establish the Safety and Efficacy of Intravitreal Injections of EYE001 (Anti-VEGF Pegylated Aptamer) Given Every 6 Weeks for 54 Weeks, in Patients with Exudative Age-Related Macular Degeneration (AMD).
-
Sub-Investigator, 2000 – 2001
+
A Phase III, Non-Randomized, Multi-Center, Unmasked Non-placebo Controlled Study of Verteporfin and Macular Degeneration (VAM).
Non-Exudative Age-Related Macular Degeneration (Dry AMD)
Current Trials:
-
Sponsor – Apellis (Closed to Enrollment)
+
Study: GALE APL2-305
A PHASE 3, OPEN-LABEL, MULTICENTER, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PEGCETACOPLAN IN SUBJECTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION -
Sponsor – ANNEXON (Closed to Enrollment)
+
Study: ARCHER ANX007-GA-01
A Phase 2, Multicenter, Randomized, Parallel-Group, Double-Masked, 4-Arm, Sham-Controlled Study of the Efficacy, Safety, and Tolerability of ANX007 Administered by Intravitreal Injection in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Previous Trials (2020 – Current):
-
2020 – 2022
Sponsor – Apellis+
Study: OAKS APL2-304
A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD) -
2020 – 2021
Sponsor – Iveric Bio+
Study: GATHER2 ISEE2008
A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM CONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF INTRAVITREAL ADMINISTRATION OF ZIMURA (COMPLEMENT C5 INHIBITOR) IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO DRY AGE-RELATED MACULAR DEGENERATION -
2020 – 2021
Sponsor – Gemini Therapeutics+
Study: ReGAtta GEM-CL-10302
A Multicenter, Open-label, Multiple Dose Study in Patients with Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Repeat Intravitreal Injections of GEM103 -
2021 – 2022
Sponsor – Genentech+
Study: GALLEGOLE GR42558
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF INTRAVITREAL INJECTIONS OF FHTR2163 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE RELATED MACULAR DEGENERATION (GAllegOLE)
Previous Trials (2015 – 2019):
-
2019 -2021
Sponsor – Genentech+
Study: GALLEGO GR40973
A PHASE II, MULTICENTER, RANDOMIZED, SINGLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND EFFICACY OF INTRAVITREAL INJECTIONS OF FHTR2163 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION (GALLEGO) -
2019 – 2019
Sponsor – Ionis+
Study: GOLDEN ISIS696844-CS5
A Phase 2, Randomized, Placebo-Controlled, Double-Masked Study to Assess Safety and Efficacy of Multiple Doses of IONIS-FB-Lrx, an Antisense Inhibitor of Complement Factor B, in Patients with Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD) -
2019 – 2020
Sponsor – Stealth BioTherapeutics+
Study: SPIAM-202
APhase 2, Randomized, Double-Masked, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Subcutaneous Injections of Elamipretide in Subjects with Age-Related Macular Degeneration with Geographic Atrophy -
Principal Investigator, 2016 – 2017
Sponsor: Genentech/Roche+
Study: OMASPECT
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF LAMPALIZUMAB IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION WHO HAVE COMPLETED A ROCHE-SPONSORED STUDY -
Principal Investigator, 2014 – 2017
Sponsor: Genentech/Roche+
Study: CHROMA – Geographic Atrophy (GA)
A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-MASKED, SHAM-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF LAMPALIZUMAB ADMINISTERED INTRAVITREALLY TO PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Diabetic Macular Edema (DME)
Current Trials:
-
Sponsor – Genentech (Recruitment/Not Yet Open)
+
Study: ELEVATUM ML43435
A PHASE IV, MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE FARICIMAB (RO6867461) TREATMENT RESPONSE IN TREATMENT-NAÏVE, UNDERREPRESENTED PATIENTS WITH DIABETIC MACULAR EDEMA -
Sponsor – Alimera Sciences (Open to Enrollment)
+
Study: NEW DAY 01-20-005
A Randomized, Masked, Controlled Study of Intravitreal ILUVIEN Implant as Baseline Therapy in Patients with Early Diabetic Macular Edema (DME) -
Sponsor – Oculis (Open to Enrollment)
+
Study: DIAMOND DX219
A Phase 2/3 Pivotal, Double-Masked, Randomized, 2-stage, Multicenter Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema -
Sponsor – Kodiak Sciences, Inc. (Closed to Enrollment)
+
Study: GLEAM KS301P104
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Secondary to Treatment-naïve Diabetic Macular Edema (DME) -
Sponsor – Genentech (Closed to Enrollment)
+
Study: PAGODA GR40550
A PHASE III, MULTICENTER, RANDOMIZED, VISUAL ASSESSOR-MASKED, ACTIVE-COMPARATOR STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA (PAGODA) -
Sponsor – Bayer/Regeneron (Closed to Enrollment)
+
Study: PHOTON VGFTe-HD-DME-1934
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA -
Sponsor – F Hoffmann-La Roche Ltd. (Closed to Enrollment)
+
Study: RHONE-X GR41987
A MULTICENTER, OPEN-LABEL EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF FARICIMAB IN PATIENTS WITH DIABETIC MACULAR EDEMA
Previous Trials (2011 – Current):
-
2019 – 2021
Sponsor – Novartis+
Study: KINGFISHER
A 12-Month, 2-Arm, Randomized, Double-Masked, Multicenter Phase III Study Assessing the Efficacy and Safety of Brolucizumab every 4 weeks versus Aflibercept every 4 weeks in Adult Patients with Visual Impairment due to Diabetic Macular Edema -
2018 – 2021
Sponsor – Genentech/Roche+
Study: RHINE
A phase III, multicenter, randomized, double-masked, active comparator-controlled study to evaluate the efficacy and safety of RO6867461 in patients with Diabetic Macular Edema (RHINE) -
Principal Investigator: 2019 – 2019
Sponsor: Thrombogenics+
Study: N/A
A PHASE 1, OPEN-LABEL, MULTICENTER, DOSE ESCALATION STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF A SINGLE INTRAVITREAL INJECTION OF THR-687 FOR THE TREATMENT OF DIABETIC MACULAR EDEMA (DME) -
Principal Investigator: 2016 – 2017
Sponsor: Genentech/Roche+
Study: BOULEVARD
A MULTIPLE-CENTER, MULTIPLE-DOSE, RANDOMZED, ACTIVE COMPARATOR-CONTROLLED, DOUBLE-MASKED, PARALLEL GROUP, 28-WEEK STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF R06867461 ADMINISTERED INTRAVITREALLY IN PATIENTS WITH DIABETIC MACULAR EDEMA -
Principal Investigator: 2016 – 2017
Sponsor: Regeneron+
Study: RUBY
A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED, PHASE 2 STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF REPEATED DOSES OF INTRAVITREAL REGN910-3 IN PATIENTS WITH DIABETIC MACULAR EDEMA
Previous Trials (2003 – 2010):
-
Sub-Investigator, 2008 – 2010
+
A 26-Week, Open-Label Study to Assess the Safety and Efficacy of 700µg Dexamethasone Posterior Segment Drug Delivery System Applicator System in the Treatment of Vitrectomized Subjects with Diabetic Macular Edema
-
Sub-Investigator, 2008 – 2010
+
A Phase 2, Randomized, Double-Masked, Placebo-Controlled, Dose-Ranging Clinical Study to Access the Safety and Efficacy of Subconjuctival Injections of Sirolimus in Patients with Diabetic Macular Edema Secondary to Diabetic Retinopathy
-
Sub-Investigator, 2008 – 2010
+
A 52-Week, Masked, Multicenter, Randomized, Controlled Trial (With Up To 13 Weeks Additional Follow-up) to Assess the Safety and Efficacy of 700µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in Combination with Laser Photocoagulation Compared with Laser Photocoagulation Alone in the Treatment of Subjects With Diffuse Diabetic Macular Edema (DME)
-
Sub-Investigator, 2007 – 2012
+
RISE – A Phase 3, Double-Masked, Multicenter, Randomized, Sham Injection-Controlled Study of the Efficacy and Safety of Ranibizumab Injection in Subjects with Clinically Significant Macular Edema with Center Involvement Secondary to Diabetes Mellitus
Sub-Investigator, 2007 – 2011
An Open Label Pharmacokinetic and Efficacy Study of 0.5µg/day and 0.2µg/day Flucinolone Acetonide Intravitreal Inserts in Subjects with Diabetic Macular Edema -
Sub-Investigator, 2006 – 2011
+
FAME – A Randomized, Double-Masked, Parallel Group, Multi-center, Dose-Finding Comparison of the Safety and Efficacy of ASI-001A 0.5µg/day and ASI-001B .02µg/day Fluocinolone Acetonide Intravitreal Inserts to Sham Injection in Subjects with Diabetic Macular Edema
-
Sub-Investigator, 2003
+
Reduction in the Occurrence of Center-Treatment Diabetic Macular Edema.
Diabetic Retinopathy Research & Clinical Trials
Current Trials:
-
Sponsor – Kodiak Sciences (Open to Enrollment)
+
Study: GLOW KS301P106
A Prospective, Randomized, Double-masked, Sham-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants with Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) -
Sponsor – OcuTerra (Recruitment/Not yet Open)
+
Study: OTT166-201
A Phase 2 Randomized, Double-Masked, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Efficacy of OTT166 Ophthalmic Solution in the Treatment of Diabetic Retinopathy (DR) -
Sponsor – F. Hoffman-La Roche Ltd. (Open to Enrollment)
+
Study: CANBERRA BP41321
A RANDOMIZED, DOUBLE-MASKED, 48-WEEK, PARALLEL-GROUP, PLACEBO-CONTROLLED, PROOF-OF-CONCEPT STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF RG7774 IN PATIENTS WITH DIABETES MELLITUS TYPE 1 OR TYPE 2 WITH TREATMENT-NAÏVE DIABETIC RETINOPATHY -
Sponsor – F. Hoffmann-La Roche Ltd. (Closed to Enrollment)
+
Study: PAVILION GR41675
A PHASE III, MULTICENTER, RANDOMIZED STUDY OF THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF THE PORT DELIVERY SYSTEM WITH RANIBIZUMAB IN PATIENTS WITH DIABETIC RETINPATHY (PAVILION)
Previous Trials:
-
Sub-Investigator, 2016 – 2019
Sponsor: Regeneron+
Study: PANORAMA
A PHASE 3, DOUBLE-MASKED, RANDOMIZED STUDY OF THE EFFICACY AND SAFETY OF INTRAVITREAL AFLIBERCEPT INJECTION IN PATIENTS WITH MODERATELY SEVERE TO SEVERE NONPROLIFERATIVE DIABETIC RETINOPATHY -
Principal Investigator, 2017 – 2019
sponsor: Aerpio+
Study: TIME-2b
PHASE 2 DOUBLE-MASKED, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY AND EFFICACY OF SUBCUTANEOUSLY ADMINISTERED AKB-9778 15 MG ONCE DAILY OR 15 MG TWICE DAILY FOR 12 MONTHS IN PATIENTS WITH MODERATE TO SEVERE NON-PROLIFERATIVE DIABETIC RETINOPATHY -
Sub-Investigator, 2007 – 2009
+
Protocol FVF4296s: An Open-Label Study to Determine the Dynamics of Regression of Neovascularization in Proliferative Diabetic Retinopathy Following Treatment with Intravitreal Ranibizumab.
Uveitis
Previous Trials:
-
Principal Investigator 2015 – 2015
+
An Open-Label, Non-Randomized, Single-Arm, Rollover Study to Continue Dosing of Gevokizumab in Subjects with Non Infectious Intermediate, Posterior, or Pan-Uveitis Who Have Controlled Ocular Inflammation After Receiving Study Drug in Study X052133
-
Principal Investigator, 2013 – 2015
+
EYEGUARD C- A RandomizEd, Double-masked, Placebo-controlled Study of the SafetY and Efficacy of GevokizUmAb in the TReatment of Subjects with Non-infectious IntermeDiate, Posterior, or Pan-uveitis Currently Controlled with Systemic Treatment
-
Principal Investigator, 2013 – 2015
+
EYEGUARD A- A RandomizEd, Double-masked, Placebo-controlled Study of the SafetY and Efficacy of GevokizUmAb in the TReatment of Active Non-infectious IntermeDiate, Posterior, or Pan-Uveitis
Branch Retinal Vein Occlusion (BRVO)
Current Trials:
-
Sponsor – F. Hoffmann-La Roche Ltd. (Closed to Recruitment)
+
Study: BALATON GR41984
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL VEIN OCCLUSION -
Sponsor – Kodiak Sciences, Inc. (Closed to Recruitment)
+
Study: BEACON KS301P103
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO) -
Sponsor – Patrick Higgins, MD (Recruitment/Open to Enrollment)
+
Study: IST
Retrospective chart review of the prevalence of positive findings in the hypercoagulability workup on patients with ischemic and nonischemic retinal vein occlusions
Previous Trials:
-
2019 – 2021
Sponsor – Novartis+
Study: Raptor
An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Branch Retinal Vein Occlusion -
Sub-Investigator, 2008 – 2010
Sponsor: Genentech+
Study: HORIZON
An Open-Label, Multicenter Extension Study To Evaluate The Safety And Tolerability Of Ranibizumab In Subjects With Choroidal Neovascularization (CNV) Secondary To Age-Related Macular Degeneration (AMD) Or Macular Edema Secondary To Retinal Vein Occlusion (RVO) Who Have Completed A Genentech-Sponsored Ranibizumab Study -
Sub-Investigator, 2007 – 2010
Sponsor: Genentech+
Study: BRAVO
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Branch Retinal Vein Occlusion -
Sub-Investigator, 2006 – 2009
+
A Six-Month, Phase 3, Multicenter, Masked, Randomized, Sham-Controlled Trial (with Six-Month Open-Label Extension) to Assess the Safety and Efficacy of 700µg and 350µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) Applicator System in the Treatment of Patients with Macular Edema Following Central Retinal Vein Occlusion or Branch Retinal Vein
-
Sub-Investigator, 2006 – 2009
+
NIH SCORE: Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection(s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion Randomized
-
Sub-Investigator, 2005
+
Two Randomized Trials to Compare the Efficacy and Safety of Intravitreal Injection (s) of Triamcinolone Acetonide with Standard Care to Treat Macular Edema: One for Central Retinal Vein Occlusion and One for Branch Retinal Vein Occlusion
Central Retinal Vein Occlusion (CRVO)
Current Trials:
-
Sponsor – F. Hoffmann-La Roche Ltd. (Closed to Recruitment)
+
Study: COMINO GR41986
A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASEKD, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL OR HEMIRETINAL VEIN OCCLUSION -
Sponsor – Kodiak Sciences, Inc. (Closed to Recruitment)
+
Study: BEACON KS301P103
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion (RVO) -
Sponsor – Patrick Higgins, MD (Recruitment/Open to Enrollment)
+
Study: IST
Retrospective chart review of the prevalence of positive findings in the hypercoagulability workup on patients with ischemic and nonischemic retinal vein occlusions
Previous Trials:
-
2019 – 2021
Sponsor – Novartis+
Study: RAVEN
An Eighteen-Month, Two-Arm, Randomized, Double Masked, Multicenter, Phase III study Assessing the Efficacy and Safety of Brolucizumab versus Aflibercept in Adult Patients with Visual Impairment due to Macular Edema secondary to Central Retinal Vein Occlusion -
Sub-Investigator, 2008 – 2010
Sponsor: Genentech+
Study: HORIZON
An Open-Label, Multicenter Extension Study To Evaluate The Safety And Tolerability Of Ranibizumab In Subjects With Choroidal Neovascularization (CNV) Secondary To Age-Related Macular Degeneration (AMD) Or Macular Edema Secondary To Retinal Vein Occlusion (RVO) Who Have Completed A Genentech-Sponsored Ranibizumab Study -
Sub-Investigator, 2007 – 2010
Sponsor: Genentech+
Study: CRUISE
A Study of the Efficacy and Safety of Ranibizumab Injection in Patients with Macular Edema Secondary to Central Retinal Vein Occlusion
Vitreomacular Adhesion
Previous Trials:
-
Principal Investigator, 2014 – 2015
+
Ocriplasmin Research to Better Inform Treatment (ORBIT)
-
Sub-Investigator, 2008 – 2010
+
A Randomized, Placebo-Controlled, Double-Masked, Multicenter Trial of Microplasmin Intravitreal Injection For Non-Surgical Treatment Of Focal Vitreomacular Adhesion
Vitreous Hemorrhage
Previous Trials:
-
Sub-Investigator, 1998 – 1999
+
A Phase III Randomized, Multi-Center, Double-Masked Placebo-Controlled Study of Vitrase in the Treatment of Non-clearing Vitreous Hemorrhage.
Retinal Detachment
Previous Trials:
-
Sub-Investigator, 2009 – 2010
+
A Multicenter, Masked, Randomized, Sham-Controlled, Parallel-Group, 3 Month Study with a 9-Month Safety Extension to Evaluate the Safety and Efficacy of Brimonidine Tartrate Posterior Segment Drug Delivery System (Brimonidine Tartrate PS DDS) Applicator System in Improving Visual Function in Patients with a Previous Rhegmatogenous Macula-off Retinal Detachment
-
Sub-Investigator, 2004 – 2005
+
A Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multi-Center, Dose-Ranging Study of Denufosol Tetrasodium (INS37217) Intravitreal Injection in Subjects with Rhegmatogenous Retinal Detachment.
Macular Telangiectasia
Current Trials:
-
Sponsor – Emmes Corporation (Closed to Enrollment)
+
Study: MacTel NHOR
A Natural History Observation and Registry Study of Macular Telangiectasia Type 2 -
Sponsor – Neurotech Pharmaceuticals Inc. (Closed to Enrollment)
+
Study: NTMT-03-B
A Phase 3 Multicenter, Randomized, Sham-Controlled Study to Determine the Safety and Efficacy of Renexus in Macular Telangiectasia Type 2
Stargardt Disease
Current Trials::
-
Sponsor – IVERIC BIO (Open to Enrollment)
+
Study: OPH2005
A Phase 2b Randomized, Double-masked, Controlled Trial to Establish the Safety and Efficacy of Zimura™ (Complement C5 Inhibitor) Compared to Sham in Subjects with Autosomal Recessive Stargardt Disease
Neurotrophic Keratopathy
Current Trials:
-
Sponsor – OYSTER POINT (Recruitment/Not yet Open)
+
Study: Olympia OPP-102
A Phase 2, Multicenter, Randomized, Controlled, Double-Masked, Clinical Trial to Evaluate the Efficacy and Safety of OC-01 (varenicline) Nasal Spray in Subjects with Neurotrophic Keratopathy (the Olympia Study)
Have Questions? Want to Elevate Your Practice? Let’s Connect!
Great teams are always looking to attract and retain great talent. Find out why we currently have a 100% partner retention rate since our inception!
Please request a no-obligation meeting, if you are interested in learning about how we can potentially benefit you or your eye care practice.
#myBtn {
display: none;
position: fixed;
bottom: 20px;
right: 30px;
z-index: 99;
font-size: 18px;
border: none;
outline: none;
background-color: #AC1A15;
color: white;
cursor: pointer;
padding: 15px;
border-radius: 4px;
font-weight: 700;
font-family: Source Sans Pro, sans-serif;
}
#myBtn:hover {
background-color:#223F80;
}
//Get the button
var mybutton = document.getElementById(“myBtn”);
// When the user scrolls down 100px from the top of the document, show the button
window.onscroll = function() {scrollFunction()};
function scrollFunction() {
if (document.body.scrollTop > 100 || document.documentElement.scrollTop > 100) {
mybutton.style.display = “block”;
} else {
mybutton.style.display = “none”;
}
}
// When the user clicks on the button, scroll to the top of the document
function topFunction() {
document.body.scrollTop = 0;
document.documentElement.scrollTop = 0;
}